What Medications Cause Yeast Infections?

Antibiotics are the most widely recognized medication trigger for yeast infections, but the list extends well beyond them. Corticosteroids, hormonal contraceptives, certain diabetes drugs, chemotherapy agents, acid-suppressing stomach medications, and newer immunosuppressants can all shift the body’s microbial balance or dampen immune defenses in ways that let Candida fungi overgrow. Understanding which medications carry this risk, and why, helps you have smarter conversations with your prescriber and take steps to reduce the chance of an uncomfortable secondary infection.

Antibiotics Are the Biggest Culprit

The connection between antibiotics and yeast infections has been documented for decades. Bacteria and fungi share real estate throughout your body, particularly in the gut and the vaginal tract. Lactobacillus bacteria are natural competitors of Candida in the vaginal environment, producing lactic acid and other metabolites that keep fungal populations in check.¹ When a broad-spectrum antibiotic wipes out those protective bacteria along with the pathogen it was prescribed for, Candida suddenly has room and resources to flourish.

Animal studies show this effect clearly: mice given broad-spectrum antibiotics developed substantially higher Candida counts in their gastrointestinal tracts compared with controls, with certain drugs like ceftriaxone and cefoperazone producing especially dramatic increases.² In humans, a large postmarketing surveillance study in England found the risk of vaginal candidiasis was highest in the second week after starting an antibiotic course, with a relative risk roughly eleven times that of women taking antidepressants (used as a comparison group). The risk remained significantly elevated in the first and third weeks as well.³

The disruption goes beyond simply removing bacterial competitors. Long-term antibiotic exposure can also impair immune cells in the gut that help contain fungal spread. Research in mice has shown that the antibiotic vancomycin reduced a key population of immune cells (Th17 cells) that normally help fight fungal infections, and this effect appeared to be driven by the resulting disruption of the gut microbiome rather than a direct drug effect on the immune cells themselves.⁴ So antibiotics create a double hit: they remove the bacterial sentries and weaken the immune response that would normally pick up the slack.

Not all antibiotics carry the same risk. Broad-spectrum drugs that kill a wide range of bacteria tend to be worse offenders than narrow-spectrum ones aimed at a single type. If you have a history of yeast infections after antibiotic courses, it is worth mentioning this to your prescriber, who may be able to choose a narrower-spectrum option or discuss whether a preventive antifungal alongside the antibiotic makes sense for you.

Hormonal Medications

Estrogen-containing medications, including combined oral contraceptive pills, hormone replacement therapy, and even the breast cancer drug tamoxifen, have been linked to yeast infections through a different pathway. Estrogen promotes the accumulation of glycogen in vaginal lining cells. That glycogen becomes fuel for both the resident Lactobacillus bacteria and for Candida. In higher-estrogen environments, Candida species show increased adhesion to vaginal cells, giving them a foothold to establish infection.⁵

This is why yeast infections tend to be more common during the luteal phase of the menstrual cycle, during pregnancy, and in people taking higher-dose estrogen formulations. Modern low-dose contraceptive pills carry a lower risk than the higher-dose formulations of earlier decades, but the association has not disappeared entirely. For postmenopausal women, tamoxifen presents an interesting case: although it blocks estrogen in breast tissue, it has estrogen-like effects on other tissues including the vaginal lining. Case reports have documented new-onset recurrent yeast infections in postmenopausal women after starting daily tamoxifen therapy.⁶

Corticosteroids, Both Inhaled and Systemic

Corticosteroids suppress the immune system, which is exactly why they work for conditions like asthma, autoimmune disease, and inflammatory flares. But immune suppression also means the body has less capacity to keep Candida in check.

Inhaled corticosteroids used for asthma and COPD are a particularly common cause of oral thrush (oropharyngeal candidiasis). The drug deposits directly on the tissues of the mouth and throat, creating localized immune suppression right where Candida lives.⁷ The same effect occurs with topical steroid preparations applied to the oral mucosa for conditions like lichen planus.⁸ Simple steps reduce this risk substantially: using a spacer device with your inhaler and rinsing your mouth with water afterward. These measures flush residual drug from the oral cavity before it can suppress local immune defenses.

Systemic corticosteroids, taken by mouth or by injection, pose a broader threat. A large systematic review and meta-analysis covering 59 studies found that corticosteroid therapy was associated with more than double the odds of invasive candidiasis and candidemia. Outcomes worsened further at higher doses, with the equivalent of more than 2 mg/kg per day of prednisolone being a significant factor in increased mortality from fungal disease.⁹ People on long-term oral steroids for conditions like lupus, severe asthma, or inflammatory bowel disease are in a different risk category than someone taking a short five-day prednisone burst for a sinus infection. But even brief courses add up if they happen frequently.

Biologic and Targeted Immunosuppressants

The newer generation of immunosuppressants used in rheumatology and dermatology targets specific branches of the immune system rather than suppressing it broadly. This precision reduces some side effects but does not eliminate infection risk. Biologics as a class carry a small but real risk of fungal infections, with candidiasis among the most commonly reported.¹⁰

Not all biologics carry the same level of risk. A retrospective study of patients with psoriasis found that fungal infections occurred in about 12% of those receiving biologic therapy, and the infections were more frequently associated with IL-17 inhibitors than with other biologic classes. Older age at the start of therapy and having diabetes also raised the odds.¹¹ This pattern makes immunologic sense: IL-17 is a key part of the body’s defense against mucosal Candida infections, so blocking it gives the fungus more room to grow.

JAK inhibitors, another class of targeted immunosuppressant used for rheumatoid arthritis, atopic dermatitis, and other inflammatory conditions, show a similar signal. Pooled safety data from clinical trials of tofacitinib found Candida was the most common opportunistic pathogen, though the absolute numbers remained low. A comparable pattern appeared with baricitinib and upadacitinib, the latter showing significantly more oral candidiasis in treatment groups than in placebo arms.¹² For most patients, the risk is manageable, but it is worth knowing about so you can recognize symptoms early rather than dismissing them.

SGLT2 Inhibitors for Diabetes

This one surprises people. SGLT2 inhibitors, a class of diabetes drugs that includes empagliflozin, dapagliflozin, and canagliflozin, work by causing the kidneys to excrete excess glucose in the urine. Lower blood sugar is the goal, but a side effect of all that sugar passing through the urinary and genital tract is that Candida suddenly has an excellent food source in a warm, moist environment.¹³

A systematic review of major clinical trials found that about 2.2% of participants taking SGLT2 inhibitors reported genital infections, compared with 0.4% of those on placebo, roughly a five-fold difference. Urinary tract infections, by contrast, occurred at similar rates in both groups.¹⁴ Most of these genital infections are mild to moderate yeast infections that respond to standard antifungal treatment. For many patients, the cardiovascular and kidney benefits of SGLT2 inhibitors outweigh this side effect, but good genital hygiene and early treatment of symptoms can keep the issue from becoming recurrent.

Chemotherapy Drugs

Chemotherapy agents increase yeast infection risk through two main routes. First, many of them hammer the bone marrow, dropping white blood cell counts to levels where the immune system can barely patrol for infections. Second, drugs that damage the mucous membranes lining the mouth and gut (a common side effect called mucositis) break down the physical barriers that normally keep Candida from invading deeper tissues. Research in animal models has shown that both mucosal damage and a depleted immune system are needed for Candida to disseminate from the gut into the bloodstream, where it becomes truly dangerous.¹⁵ Oral mucositis combined with candidiasis poses a risk of systemic candidemia in cancer patients on chemotherapy.¹⁶

Because the stakes are higher in immunocompromised patients, oncologists often prescribe preventive antifungal medication during chemotherapy or bone marrow transplantation. A landmark trial in bone marrow transplant recipients demonstrated that prophylactic fluconazole reduced both systemic and superficial fungal infections.¹⁷ This preventive approach has since become standard practice in many cancer treatment protocols.

Proton Pump Inhibitors and Acid-Reducing Drugs

Medications that reduce stomach acid, particularly proton pump inhibitors like omeprazole and pantoprazole, create an environment in the upper digestive tract where Candida can thrive. Normally, stomach acid acts as a barrier against fungal overgrowth. When you suppress that acid for weeks or months, you remove one of the body’s natural antifungal defenses.

A study comparing patients taking PPIs to untreated individuals found that Candida colonization of the gastric mucosa was significantly increased after PPI treatment, with Candida identified as a microbial biomarker for the PPI-treated group.¹⁸ Another study found that the use of common acid-suppressing drugs raised the risk of gastric candidiasis dramatically: omeprazole increased it by roughly 13-fold, pantoprazole by about 9-fold, and even the older H2 blocker ranitidine by about 11-fold.¹⁹

This is less about getting an obvious “yeast infection” you would notice and more about silent overgrowth in the esophagus and stomach, sometimes discovered incidentally during an endoscopy. For people who truly need long-term acid suppression, the risk is generally accepted as part of the tradeoff. But these findings are one more reason why gastroenterologists encourage patients to use the lowest effective dose and to periodically reassess whether ongoing PPI therapy is still necessary.

Spermicides Containing Nonoxynol-9

The evidence here is genuinely mixed, which is worth knowing because you will find confident claims on both sides. In laboratory experiments, nonoxynol-9, the active ingredient in most spermicidal products, increased the adhesion of Candida species to human cells by two- to nearly seven-fold.²⁰ However, a clinical study comparing spermicide users with non-users found no significant difference in Candida isolation rates between the two groups.²¹ What nonoxynol-9 does appear to do more consistently is disrupt the vaginal bacterial balance in a dose-dependent way, promoting shifts toward bacterial vaginosis.²² Whether that bacterial disruption then opens the door to secondary yeast overgrowth in some women remains an open question. If you suspect spermicidal products are contributing to recurrent yeast infections, switching to a non-spermicidal barrier method or a different contraceptive approach is a reasonable step to try.

Why Some People Are More Susceptible

Two people can take the same antibiotic at the same dose, and only one develops a yeast infection. The medication is the trigger, but several background factors determine whether that trigger fires. Uncontrolled diabetes raises baseline risk because elevated blood sugar feeds Candida throughout the body. Pregnancy increases estrogen and glycogen levels in vaginal tissue, amplifying the hormonal pathway described earlier. Being immunocompromised for any reason, whether from HIV, organ transplant medications, or simply from aging, lowers the threshold at which a medication-induced shift becomes an infection.

People taking multiple medications on this list face compounding risks. A patient on systemic corticosteroids and a broad-spectrum antibiotic simultaneously is getting hit from two directions: disrupted bacterial flora and suppressed immune surveillance. Cancer patients on chemotherapy who also receive broad-spectrum antibiotics for infection prophylaxis are in a particularly vulnerable position, which is why antifungal prophylaxis is often added to their regimen.

Do Probiotics Help Prevent Medication-Related Yeast Infections?

Given that the mechanism behind antibiotic-associated yeast infections involves depleting protective bacteria, the idea of replacing them with probiotics sounds logical. Some clinical data does support the concept broadly: a review found evidence that probiotics can reduce oral, vaginal, and gut Candida colonization, and in some cases alleviate symptoms of candidiasis.²³

However, the most rigorous trial specifically testing whether Lactobacillus supplements prevent yeast infections after antibiotic use told a less encouraging story. A randomized controlled trial comparing oral Lactobacillus, vaginal Lactobacillus, and placebo found no benefit from either form of probiotic. The trial was actually stopped early because interim analysis showed the probiotics were clearly not working.²⁴ The disconnect between the general evidence and this specific trial may come down to strain selection, dose, timing, or just the difficulty of re-establishing a complex microbial community by dropping in a single species. Probiotics remain a popular recommendation, but the evidence for preventing post-antibiotic yeast infections specifically is weaker than most people assume.

Antifungal Resistance and Repeated Infections

An underappreciated consequence of medication-induced yeast infections is what happens when they keep recurring and you keep treating them with over-the-counter antifungals. The most commonly used drug for Candida infections, fluconazole, belongs to the azole class. Certain Candida species that are not the usual culprit (so-called non-albicans species) show intrinsic resistance to azoles, and the selective pressure from repeated treatment can shift the population of Candida in your body toward these harder-to-treat species. Candida albicans itself can also develop high-level resistance over time with repeated exposure.²⁵

This means that if you are on a medication that predisposes you to frequent yeast infections, treating each episode with the same over-the-counter product may work initially but become less effective over time. If you find that your go-to treatment stops resolving symptoms after a few days, or if infections come back within weeks of clearing, it is worth getting a culture done rather than continuing to self-treat. A culture identifies the specific Candida species and can guide your provider toward an antifungal that actually works against it.

Vaginal Douching Makes Things Worse, Not Better

When yeast infections keep showing up, it is tempting to try to “clean out” the problem. Vaginal douching remains surprisingly common despite decades of evidence that it does more harm than good. Douching disrupts the normal vaginal flora and can push pathogens further into the reproductive tract, raising the risk of bacterial vaginosis and other complications.²⁶ If a medication is already disturbing your microbial balance, douching compounds the disruption rather than correcting it. The vagina is self-cleaning; external washing of the vulva with plain water or a gentle, unscented cleanser is all that is needed.

Practical Steps When You Cannot Stop the Medication

Sometimes the drug causing the problem is not one you can easily swap or stop. You are not going to discontinue chemotherapy because of thrush, and stopping an SGLT2 inhibitor that is protecting your kidneys may not be the right call either. In those situations, the approach shifts to risk reduction and early management.

• Inhaled steroids: Use a spacer device, rinse your mouth with water after each dose, and spit rather than swallow the rinse water.
• SGLT2 inhibitors: Keep the genital area clean and dry, wear breathable fabrics, and treat any early symptoms promptly rather than waiting.
• Antibiotics: Ask your provider whether a narrower-spectrum drug is an option. For people with a strong history of post-antibiotic yeast infections, some clinicians prescribe a single dose of fluconazole to take at the end of the antibiotic course.
• Chemotherapy: Antifungal prophylaxis is often built into the treatment plan. If it is not, and you are developing oral or genital symptoms, bring it up early.
• Systemic steroids: If you are on a long-term taper, discuss with your provider whether the dose can be minimized and whether antifungal monitoring makes sense.

Recognizing symptoms early matters more than most people realize. A mild yeast infection treated promptly is a minor nuisance. The same infection left untreated in someone who is immunosuppressed can progress to something much more serious, particularly if Candida enters the bloodstream. Pay attention to new oral white patches, genital itching, or changes in discharge, and report them rather than assuming they will resolve on their own.